Atea Pharmaceuticals, Inc. (AVIR)
D
Pipeline Grade
Financial Position (from SEC Filings)
$79.3M
Cash & Equivalents
$46.4M
Quarterly Burn Rate
5 mo
Est. Cash Runway
$399M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase3 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07037277 | C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV | PHASE3 | Active Not Recruiting | 880 |
| NCT06868264 | C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV | PHASE3 | Active Not Recruiting | 880 |
| NCT07314346 | Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone | PHASE1 | Recruiting | 32 |
| NCT06911320 | Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepati... | PHASE1 | Recruiting | 28 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.